TIGERTRIEVER (TM) 13 is the first device shown to meet safety and effectiveness endpoints for restoring blood flow in smaller but critical areas of the brain, accounting for almost 50% of all ischemic ...
bDepartment of Biostatistics and Epidemiology, University Hospital of Saint-Louis, Paris, France cDepartment of Hematology, University Hospital of Saint-Louis, Paris, France dDepartment of Hematology, ...
Methods: In this 6-month, 2-arm, multicenter, unblinded randomized controlled trial, patients aged 18 years or older diagnosed with T2DM were randomly assigned (1:1) to an intervention group (IG) ...
A novel collaboration may establish a framework to help researchers overcome regulatory barriers they often face when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results